Acute myeloid leukemia (AML) initiation requires multiple rate-limiting mutations to cooperatively reprogram progenitor cell identity. For example, FLT3 internal tandem duplication (FLT3ITD) mutations cooperate with a variety of different initiating mutations to reprogram myeloid progenitor fate. These initiating mutations often skew toward either pediatric or adult AML patient populations, though FLT3ITD itself occurs at similar frequencies in both age groups. This raises the question of whether FLT3ITD might induce distinct transcriptional programs and unmask distinct therapeutic vulnerabilities when paired with pediatric, as opposed to adult AML-initiating mutations. To explore this possibility, we compared AML evolution in mice that carried Flt3ITD/NUP98-HOXD13 (NHD13) or Flt3ITD/Runx1DEL mutation pairs, which are respectively most common in pediatric and adult AML. Single-cell analyses and epigenome profiling revealed distinct interactions between Flt3ITD and its cooperating mutations. Whereas Flt3ITD and Flt3ITD/Runx1DEL caused aberrant expansion of myeloid progenitors, Flt3ITD/NHD13 drove the emergence of a pre-AML population that did not resemble normal hematopoietic progenitors. Differences between Flt3ITD/Runx1DEL and Flt3ITD/NHD13 cooperative target gene expression extended to fully transformed AML as well. Flt3ITD/NHD13 cooperative target genes were enriched in human NUP98-translocated AML. Flt3ITD/NHD13 selectively hijacked type I interferon signaling to drive expansion of the pre-AML population. Blocking interferon signaling delayed AML initiation and extended survival. Thus, common AML driver mutations, such as FLT3ITD, can coopt different mechanisms of transformation in different genetic contexts. Furthermore, pediatric-biased NUP98 fusions convey actionable interferon dependence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082380PMC
http://dx.doi.org/10.1182/blood.2022016889DOI Listing

Publication Analysis

Top Keywords

aml initiation
12
aml
9
cell identity
8
interferon dependence
8
initiating mutations
8
pediatric adult
8
adult aml
8
mutations flt3itd
8
pre-aml population
8
flt3itd/nhd13 cooperative
8

Similar Publications

Purine-rich element binding protein alpha: a DNA/RNA binding protein with multiple roles in cancers.

Mol Med

January 2025

Nanjing Women and Children's Healthcare Hospital, Maternal and Child Health Institute, Women's Hospital of Nanjing Medical University, 123 Tianfei Alley, Mochou Road, Nanjing, China.

Proteins that bind to DNA/RNA are typically evolutionarily conserved with multiple regulatory functions in transcription initiation, mRNA translation, stability of RNAs, and RNA splicing. Therefore, dysregulation of DNA/RNA binding proteins such as purine-rich element binding protein alpha (PURα) disrupts signaling transduction and often leads to human diseases including cancer. PURα was initially recognized as a tumor suppressor in acute myeloid leukemia (AML) and prostate cancer (PC).

View Article and Find Full Text PDF

Background: may cause fatal infections in immunocompromised patients. This is the first case report of invasive infection at an academic-tertiary care center in Palestine.

Case Presentation: We report a 36-year-old woman who presented with fever and severe neutropenia and was found to have AML/Non M3.

View Article and Find Full Text PDF

and mRNA expression-based risk stratification of acute Myeloid Leukemia.

Leuk Res Rep

December 2024

Independent Researcher, Gimpo-si, Gyeonggi-do 10090, South Korea.

Prognostication of acute myeloid leukemia (AML) at initial diagnosis relies on identification of pre-determined underlying genetic abnormalities. Nevertheless, the disease course of AML remains highly unpredictable and robust reliable prognostic biomarkers for newly diagnosed AML are lacking. We retrospectively explored two publicly available AML RNA-Seq datasets and found that inferior overall survival was associated with high- and low- transcript levels (" / ") compared to low- and high- transcript levels (" / ") in adult AML patients, with a hazard ratio for death of at least 2.

View Article and Find Full Text PDF

Background: Cancer rates are rising rapidly, causing global mortality. According to the World Health Organization (WHO), 9.9 million people died from cancer in 2020.

View Article and Find Full Text PDF

Background: Few Chinese study compared the impacts of idarubicin and daunorubicin based "3+7" intensive chemotherapies on early and long-term outcomes of AML patients through exploring their real-world data.

Patients And Methods: Our none promyelocytic AML patients inducted with "3+7" regimens were studied to find out the factors relating with induction response and long term survival.

Results: Idarubicin induction was related with less chemotherapy refractory rate comparing with daunorubicin induction (10% vs 25%, P = 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!